Cargando…
Bone marrow-derived NCS-01 cells for ischemic stroke
Stroke stands as one of the most common causes of death among adults worldwide. Currently, tissue plasminogen activator serves as the only approved drug by the Food and Drug Administration for the treatment of acute ischemic stroke. Stem cell therapy serves as a viable treatment option and has been...
Autores principales: | Saft, Madeline, Koga, Minako, Borlongan, Cesario V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057097/ https://www.ncbi.nlm.nih.gov/pubmed/34084978 http://dx.doi.org/10.4103/bc.bc_23_21 |
Ejemplares similares
-
Bone Marrow-Derived NCS-01 Cells Advance a Novel Cell-Based Therapy for Stroke
por: Brown, John, et al.
Publicado: (2020) -
Translating intracarotid artery transplantation of bone marrow‐derived NCS‐01 cells for ischemic stroke: Behavioral and histological readouts and mechanistic insights into stem cell therapy
por: Kaneko, Yuji, et al.
Publicado: (2019) -
Stem Cells as Drug-like Biologics for Mitochondrial Repair in Stroke
por: Farooq, Jeffrey, et al.
Publicado: (2020) -
LncRNAs Stand as Potent Biomarkers and Therapeutic Targets for Stroke
por: Fan, Junfen, et al.
Publicado: (2020) -
Melatonin—A Potent Therapeutic for Stroke and Stroke-Related Dementia
por: Sadanandan, Nadia, et al.
Publicado: (2020)